Evan F. Lanuza, n/a

Director
Kern Medical
Paso Robles, California, United States

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Presentation(s):

• 870 - Olorofim for the treatment of invasive mould infections in patients with limited or no treatment options: Comparison of interim results from a Phase 2B open-label study with outcomes in historical control populations (NCT03583164, FORMULA-OLS, Study 32)

  Friday, October 21, 2022
  11:00 AM – 11:15 AM US ET